Header Logo

Connection

Lynn Morris to Reverse Transcriptase Inhibitors

This is a "connection" page, showing publications Lynn Morris has written about Reverse Transcriptase Inhibitors.
Connection Strength

2,238
  1. HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
    View in: PubMed
    Score: 0,662
  2. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2015 Feb; 59(2):960-71.
    View in: PubMed
    Score: 0,450
  3. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013; 18(7):915-20.
    View in: PubMed
    Score: 0,407
  4. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr. 2015 Jan 01; 68(1):55-61.
    View in: PubMed
    Score: 0,113
  5. Novel indole based NNRTIs with improved potency against wild type and resistant HIV. Bioorg Med Chem Lett. 2014 Sep 15; 24(18):4376-4380.
    View in: PubMed
    Score: 0,110
  6. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20.
    View in: PubMed
    Score: 0,103
  7. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011 Mar 15; 203(6):798-802.
    View in: PubMed
    Score: 0,086
  8. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009 Apr 27; 23(7):809-16.
    View in: PubMed
    Score: 0,076
  9. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 2006 Feb; 50(2):694-701.
    View in: PubMed
    Score: 0,061
  10. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109.
    View in: PubMed
    Score: 0,058
  11. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS. 2003 Jul 25; 17(11):1698-700.
    View in: PubMed
    Score: 0,051
  12. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13. BMC Infect Dis. 2019 Sep 16; 19(Suppl 1):787.
    View in: PubMed
    Score: 0,039
  13. Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother. 2009 Jul; 53(7):3056-64.
    View in: PubMed
    Score: 0,019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.